XML 32 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1

13. Restructuring Costs (Notes)

9 Months Ended

Sep. 30, 2017

Restructuring Costs [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

13.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three and nine months ended September 30, 2017. The liability of $6.5 million as of September 30, 2017 encompassed a short-term liability of $3.8 million and a long-term liability of $2.7 million, and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of less than $0.1 million and $(0.2) million, and in Selling, general and administrative expense of less than $0.1 million and $0.3 million in the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2017, respectively. The amounts adjusted were primarily due to employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our restructuring reserves for severance (in millions):

		Life Science				Clinical Diagnostics				Total
Balance at December 31, 2016		$	3.2			$	5.8			$	9.0
Charged to expense		—				—				—
Adjustment to expense		—				—				—
Cash payments		(1.2		)		(2.2		)		(3.4		)
Foreign currency translation losses		0.3				0.6				0.9
Balance at September 30, 2017		$	2.3			$	4.2			$	6.5

Restructuring Costs for GnuBIO, Inc.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It is included in our Clinical Diagnostics segment’s results of operations as a division, and is primarily based in Massachusetts. In September 2017, management announced that it is closing its GnuBIO research program facilities in Massachusetts. As a result, we recorded restructuring charges related to severance and employee benefits of $2.9 million, and asset write-offs of $5.5 million. We expect the majority of the employee related amounts to be paid by the end of 2017.

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringCostsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration